De-merger of Identified Business of Arco Lab Private Limited ( Arco Lab ), a wholly owned subsidiary of the Company
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Arco Lab Private Limited (a wholly owned subsidiary of Strides Pharma) has approved a Scheme of Arrangement to demerge its Life Sciences and Digital Innovation businesses (called the 'Identified Business') into Pivot Path Private Limited, which is currently a wholly owned subsidiary of Arco Lab. The appointed date for the demerger is April 10, 2025. Shareholders of Arco Lab (i.e., Strides) will receive equity shares of Pivot Path at a 1:1 exchange ratio, with no cash consideration involved. As a result, Arco Lab's investment in Pivot Path will be cancelled, and Pivot Path will become a direct wholly owned subsidiary of Strides. The scheme is subject to shareholder, creditor, and NCLT approvals. Pivot Path will not seek stock exchange listing.
This is an internal group restructuring with no change in ultimate ownership for Strides shareholders and no cash outflow. It streamlines the corporate structure by placing the Life Sciences and Digital Innovation businesses directly under Strides, potentially enabling sharper focus and future strategic flexibility, though near-term stock impact is expected to be limited.